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http://www.biomedcentral.com/1472-6882/14/303RESEARCH ARTICLE Open AccessPolysaccharopeptide enhanced the anti-cancer
effect of gamma-tocotrienol through activation
of AMPK
Ji Liu1†, Eunice Yuen-Ting Lau2†, Jiezhong Chen3, Joan Yong1, Kai Dun Tang1, Jessica Lo2, Irene Oi-Lin Ng2,
Terence Kin-Wah Lee2,5* and Ming-Tat Ling1,4*Abstract
Background: Prostate cancer (PCa) frequently relapses after hormone ablation therapy. Unfortunately, once
progressed to the castration resistant stage, the disease is regarded as incurable as prostate cancer cells are highly
resistant to conventional chemotherapy.
Method: We recently reported that the two natural compounds polysaccharopeptide (PSP) and Gamma-tocotrienols
(γ-T3) possessed potent anti-cancer activities through targeting of CSCs. In the present study, using both prostate
cancer cell line and xenograft models, we seek to investigate the therapeutic potential of combining γ-T3 and PSP in
the treatment of prostate cancer.
Result: We showed that in the presence of PSP, γ-T3 treatment induce a drastic activation of AMP-activated protein
kinase (AMPK). This was accompanied with inactivation of acetyl-CoA carboxylase (ACC), as evidenced by the
increased phosphorylation levels at Ser 79. In addition, PSP treatment also sensitized cancer cells toward γ-T3-induced
cytotoxicity. Furthermore, we demonstrated for the first time that combination of PSP and γ-T3 treaments significantly
reduced the growth of prostate tumor in vivo.
Conclusion: Our results indicate that PSP and γ-T3 treaments may have synergistic anti-cancer effect in vitro and
in vivo, which warrants further investigation as a potential combination therapy for the treatment of cancer.
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Prostate cancer (PCa) is the most common type of solid
tumor in men around the world and is a leading cause
of morbidity and mortality. Due to the slow growing
nature of the tumor, many prostate cancer patients have
already developed metastatic disease, where surgery is
no longer feasible. The only frontline treatment available
for the PCa patient at the advanced stage is hormone
ablation therapy. Unfortunately, the majority of patients
will eventually relapse and develop castration-resistant* Correspondence: tkwlee@hku.hk; mingtat.ling@qut.edu.au
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unless otherwise stated.prostate cancer (CRPC), a fatal and terminal stag. There is
currently no curative treatment against hormone refrac-
tory prostate cancer (HRPC) since the tumor frequently
develops resistance to conventional chemotherapy, with
the most effective treatment (Docetaxel, a microtubule-
disrupting agent) extend patient survival for an average of
only two months and is associated with significant side ef-
fects [1]. Thus, there is an urgent need for a better therapy
for CRPC that shows improved treatment efficiency and
minimal side effects.
We and other have reported that a number of bioactive
food compounds have potent anti-cancer effect, particu-
larly against the cancer stem cell (CSC) population, which
has been suggested to play a key role in the development
and progression of prostate cancer. For example, we pre-
viously demonstrated that gamma-tocotrienol (γ-T3) ex-
tracted from palm oil suppresses prostasphere formationThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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addition, a triterpene extracted from fruits was also found
to target liver CSCs and sensitize cells to cisplatin treat-
ment [3]. More recently, we have shown that polysac-
charopeptide (PSP) isolated from Turkey tail (known as
Coriolus versicolor or Yun-zhi) also inhibit prostate CSC
self-renewal in vitro and prevent prostate cancer develop-
ment in vivo [4]. These findings demonstrated the poten-
tial of natural compounds as effective anti-cancer agent
through targeting of CSCs.
Although natural compounds such as γ-T3 or PSP both
demonstrated potent anti-cancer effect, they were found
to act through different downstream mechanisms. For ex-
ample, γ-T3 has been shown to inhibit prostate cancer cell
invasion by suppressing the epithelial to mesenchymal
transition [5]. It was also found to regulate a number of
key prosurvival signaling pathways, such as NF-KappaB
[6] and PI3K [7], and as a result induce apoptosis of the
cancer cells. PSP, on the other hand, was found to inhibit
CSC self-renewal without affecting the survival of the can-
cer cells. In particular, oral intake of PSP was found to
have immunomodulatory effect in breast cancer patients,
as evidenced by the significant induction of the T-helper
lymphocytes and the B-lymphocytes [8]. It is thus temp-
ting to speculate that combination of these compounds
may achieve a synergistic anti-cancer effect through tar-
geting of multiple signalling pathways.
Here, we investigated the in vitro and in vivo anti-
cancer effect of combining PSP and γ-T3. We found that
the PSP significantly enhanced the cytotoxicity effect of
γ-T3 on cancer cells, which was associated with activa-
tion of AMPK. Meanwhile, treatment of the cells with
PSP and γ-T3 also lead to inactivation of the acetyl-CoA
carboxylase (ACC). Furthermore, oral supplementation
of a combined dosage of PSP and γ-T3 was found to
have a more potent anti-tumor effect than either agent
alone. Our findings highlight the potential of combining
PSP with γ-T3 in the treatment of cancer.
Methods
Polysaccharopeptide (PSP) and gamma-tocotrienol (γ-T3)
PSP extracted from Yun-zhi was kindly provided by
Wonder Herb Health Products, Ltd. The PSP powder was
dissolved in autoclaved Milli Q water at a concentration
of 30 mg/ml by mixing in a rotator at room temperature
overnight. The PSP solution was stored at -20°C. For cell
culture study, PSP stock was sterilized with 0.2 μm filtra-
tion prior to use. In the animal study, PSP was fed directly
to mice. γ-T3 was provided by Davos Life Science Pte.
Ltd, Singapore and was dissolved in absolute ethanol
(2.5 μg/ml, 3.5 μg/ml and 5 μg/ml) and stored at -20°C.
Using the corresponding T3 isomers as reference stan-
dards, the purity of γ-T3 was verified to be ≥97% by high
performance liquid chromatography (HPLC).Cell lines and culture conditions
Prostate cancer cell lines PC3 (ATCC, Rockville, MD)
were maintained in RPMI 1640 medium (Invitrogen,
Carlsbad, CA) supplemented with 1% (w/v) penicillin-
streptomycin (Invitrogen, Carlsbad, CA) and 5% fetal
bovine serum (Invitrogen, Carlsbad, CA). All cell types
were kept at 37°C in a 5% CO2 environment.Generation of PC-3 cells stably expressing GFP
A GFP-expressing PC-3 cell line, PC3-GFP, was generated
using the Viralpower Lentiviral gene expression system
(Invitrogen, Carlsbad, CA) according to the manufac-
turer’s instructions. Briefly, supernatant containing the
lentivirus was mixed with polybrene (8 μg/ml) and used to
infect PC-3 cells. After infection, positive transfectants
were selected as a pool by treatment with blasticidine
(10 μg/ml) for six days.Western blotting
Detailed experimental procedures have been described
previously [4]. Briefly, whole cell lysates were prepared by
resuspending cell pellets in cell lysis buffer (20 mM Tris-
HCl, 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1%
Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-
glycerophosphate, 1 mM Na3VO4, 1 μg/ml leupeptin).
Protein concentration was determined using Pierce BCA
Protein Assay Kit (Pierce, Rockford, IL). Protein extract
was loaded onto an SDS-polyacrylamide gel, separated by
electrophoresis and then transferred to a PVDF mem-
brane (Millipore, Billerica, MA). The membrane was then
incubated with primary antibodies against AMPKα, phos-
pho-AMPKα (Thr172) and phospho-ACC (Ser79) (Cell
signaling, Technology Inc, Beverly, MA) and γ-tubulin
(Sigma-Aldrich, St Louis, MO) overnight at 4°C. After
washing with TBS-T, the membrane was incubated with
rabbit IgG secondary antibodies, and the signals were vi-
sualized using the ECL western blotting system (Millipore,
Billerica, MA).Colony formation assay
The colony formation assay was carried out as described
previously [2]. Briefly, PC3 cells were seeded 12-well
plate (100 cells per well). Cells were cultured for 14 days
in the presence of γ-T3 at 2.5 μg/mL, 3.5 μg/mL or
5 μg/mL and/or PSP at 30 μg/mL. At the end of the
experiment, the number of the colonies formed was
counted. Colony forming ability was normalized as a
percentage of untreated cells. Each experiment was re-
peated in triplicate, and each data point represents the
mean and standard derivation. Statistical difference was
determined by Student t-test and was considered as sig-
nificance if p < 0.05.
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The xenograft was established in 4- to 6-week-old male
athymic nude mice (BALB/c-nu/nu) with GFP-labeled
PC3 prostate cancer cell line (PC3-GFP). Treatment was
started once the size of the xenograft reached approxi-
mately 4 × 4 mm2 (length × width) in size after subcutane-
ous injection of 1 × 106 of PC3-GFP cells, during which
the mice were randomly assigned into four groups and
each group consisted of 5 mice: 1) γ-T3 (50 mg/Kg/day),
2) PSP (300 mg/Kg/day), and 3) γ-T3 (50 mg/Kg/day) plus
PSP (100 mg/Kg/day) and 4) DMSO and PBS as a control.
γ-T3 and PSP were administered to the mice intraperi-
toneally and orally respectively. After 30 days of various
treatments, the effects on tumor growth were measured
and recorded with a Maestro imaging system (CRI Inc.
Woburn, MA). Statistical difference was determined by a
two-tailed t-test and was considered significant if p < 0.05.
All the animal experiments have been approved by the
animal ethics committee of The University of Hong Kong
and the surgical and animal handling procedures were
carried out according to the guidelines of the Committee
on the Use of Live Animals in Teaching and Research
(CULATR), The University of Hong Kong.
Immunostaining
Tissues were formalin fixed and paraffin embedded. Four-
micrometer sections were cut, dewaxed in xylene and
graded alcohols, hydrated, and washed in PBS. After
pretreatment in a microwave oven (12 minutes in sodium
citrate buffer [pH 6]), the endogenous peroxidase was
inhibited by 0.3% H2O2 for 30 minutes, and the sections
were incubated with 10% normal goat serum for 30 mi-
nutes. Rabbit polyclonal anti–phospho-AMPKα (Thr172)
(1:100) and anti-phospho-ACC (Ser79) (Cell Signal Tech-
nology) was applied overnight in a humidity chamber atFigure 1 Inhibition of colony forming ability by PSP and γ-T3. (A&B). PC
and γ-T3. Colonies formed at the end of the experiment were stained and
(A) or as actual colony no (B). All data represent mean and SD.4°C. (A standard avidin-biotin peroxidase technique (Dako)
was applied. Briefly, biotinylated goat anti-mouse immu-
noglobulin and avidin-biotin peroxidase complex were ap-
plied for 30 minute each, with 15-minute washes in PBS.
The reaction was finally developed with the Dako Liquid
DAB + Substrate Chromogen System (Dako). Slides were
imaged on an Aperio Scanscope CS imager, generating
0.43-μm/pixel whole slide images.
Results
PSP enhances the cytotoxic effect of γ-T3
To study the synergistic effect between PSP and γ-T3,
colony formation assay was performed with prostate
cancer cell line PC3 in the presence or absence of PSP
and/or γ-T3. As shown in the Figure 1, PSP at 30 μg/ml
resulted in a decrease of colonies (~50%) when com-
pared to control. Interestingly, γ-T3 at concentrations of
2.5 μg/ml and 3.5 μg/ml did not have any obvious effect
on colony forming ability of the cells. However, when
administered simultaneously with PSP, it reduced the
number of colonies by approximately 65% and 85%, re-
spectively. In addition, 5 μg/ml of γ-T3 leads to a 45%
reduction in cell number, which when combined with
PSP, almost led to complete inhibition of colony forma-
tion. These data suggest that PSP and γ-T3 work syner-
gistically in reducing the viability of the cancer cells.
Synergistic effect of PSP and γ-T3 on AMPK activation
To examine the potential mechanism behind the syner-
gistic effect between PSP and γ-T3, we then examine the
combine effect of PSP and γ-T3 on a series of cell signal-
ling pathways involved in CSC survival/metabolism.
While the effect of γ-T3 on the cell survival pathways
such as AKT and JNK was not affected by PSP treatment
(data not shown), we found that when the cells were-3 cells were allowed to grow under different combinations of PSP
counted. The result was presented as percentage relative to control
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with 30 μg/ml of PSP for 24 hr, the phosphorylation levels
of AMPK at Thr172 were significantly up-regulated in the
PSP and γ-T3 combination group compared with either
PSP or γ-T3 (Figure 2). Meanwhile, the total AMPK
protein levels were not significantly affected by the treat-
ments, suggesting that the induction of AMPK phospho-
rylation is not a result of increased AMPK transcriptional
level. It is notable that although γ-T3 alone at 5 μg/ml also
leads to the phosphorylation of AMPK, a more profound
effect was observed in the combination therapy group
(Figure 2). Strikingly, the combined treatment of PSP and
γ-T3 also upregulated the phosphorylation levels of ACC,
a direct downstream target of AMPK. Since ACC phos-
phorylation by AMPK results in inactivation of its activity,
our findings suggest that PSP and γ-T3 cooperate to pro-
mote AMPK activation, leading to suppression of the
ACC function.
Combination of PSP and γ-T3 is a novel strategy against
prostate cancer
We examined the therapeutic role of combined effect of
γ-T3 and PSP in vivo using PC3-GFP cells. AthymicFigure 2 Effect of PSP and γ-T3 treatments on AMPK signalling pathwa
of phospho-AMPKα (Thr172), phospho-ACC (Ser79) and tubulin (as loading co
quantitated with gel documentation system and the data was presented as fnude mice were allografted with PC3-GFP cells and were
divided into γ-T3 alone, PSP alone, combined γ-T3 and
PSP and control (DMSO and PBS). After 30 days of
treatment, the tumor was imaged using Maestro imaging
system. The representative mice are shown in Figure 3A.
γ-T3 reduced the tumor volumes in a manner approxi-
mately two folds and the effect is similar to PSP. In
addition, γ-T3 combined with PSP had significant inhi-
bitory effects on PC3-GFP growth in vivo compared to
the DMSO and PBS control group (P < 0.01) (Figure 3B).
During the experiment, no signs of toxicity (infection,
diarrhea, or loss of body weight) were observed in the
animals undergoing treatment with PSP and γ-T3 when
compared with DMSO and PBS. To confirm whether
the growth suppressive effect γ-T3 in combination with
PSP is due to induction of autophagy, we examined and
compared the expression of phospho-AMPKα (Thr172)
and phospho-ACC (Ser79) in the tumor xenograft tis-
sues of treated and control groups. Consistent to the
in vitro observation (Figure 2), we found that increased
expression in xenograft tumor of both phospho-AMPKα
(Thr172) and phospho-ACC (Ser79) in mice treated with
γ-T3 and PSP when compared with the control (Figure 4),y. PC-3 were treated with the indicated compounds for 24 hr. (A) Levels
ntrol) were examined by Western blotting. (B) Western blot result was
old change relative to the control.
Figure 3 In vivo treatment of PSP and γ-T3. The in vivo therapeutic effect of PSP and γ-T3 was examined in a nude mouse model with PC3-GFP
cells. Nude mice were randomized into four groups, each consisting of five animals. Each group was treated daily for 30 days with either γ-T3
(50 mg/Kg/day), PSP (300 mg/Kg/day), γ-T3 (50 mg/Kg/day) plus PSP (300 mg/Kg/day and or DMSO and PBS as the control group. (A) Tumor volume
in each group was evaluated using Maestro imaging system. Representative mice in each group were shown. (B) γ-T3 administration reduced the
tumor size by ~2 folds as compared with control and its effect was similar to PSP alone. The combination of γ-T3 and PSP exhibited a synergistic effect
on tumor suppression (P < 0.01, t test).
Liu et al. BMC Complementary and Alternative Medicine 2014, 14:303 Page 5 of 6
http://www.biomedcentral.com/1472-6882/14/303suggesting that γ-T3 in combination with PSP leads to
AMPK activation and subsequent inactivation of ACC
in vivo.
Discussion
PSP and γ-T3 have been studied extensively in separate
studies for their potent anti-cancer effects against a wide-
range of cancer cells which includes breast [9-11], liver
[12], prostate cancer [13] and melanoma. Despite of this,
the mechanisms underlying their anti-cancer effects re-
main poorly understood. Here, we demonstrated for the
first time that PSP acts synergistically with γ-T3 to sup-
press the survival of prostate cancer cells. This combined
effect of PSP and γ-T3 was associated with activation of
the AMPK signalling pathway, leading to inactivation of
the ACC. The synergistic effect of PSP and γ-T3 was fur-
ther confirmed with a prostate cancer xenograft models.Figure 4 PSP and γ-T3 activates AMPK signalling pathway in vivo. Imm
mice with the indicated treatment. Consecutive sections were stained with
Note that an increase in cytoplasmic expression of both proteins was obseγ-T3 is one of the constituents of Vitamin E which
has been shown to possess anti-oxidative, anti-cardio-
vascular disease, neuroprotective and anticancer effects
[14]. Recently, γ-T3 was also reported to sensitize can-
cer cells to chemotherapeutic drugs [5,15]. γ-T3 is
known to target a number of key cell signalling pathway
frequently activated in cancer cells. Meanwhile, γ-T3
treatment has also been shown to induce autophagy in
cancer cells. Although AMPK signalling cascade plays a
key role in the induction of autophagy in normal and
cancer cells [16], whether γ-T3 regulates AMPK in can-
cer cells is currently unclear. The fact that both phos-
phorylated AMPK and ACC were upregulated by γ-T3
treatment clearly support that γ-T3 activates AMPK
and its downstream signalling cascade in cancer cells.
Meanwhile, this effect of γ-T3 appears to be dose
dependent as a lower dosage of γ-T3 (2.5 μg/ml) failedunostaining was performed on xenograft tumor collected from the
antibody against phospho-AMPKα (Thr172) and phospho-ACC (ser79).
rved in tumors co-treated with γ-T3 and PSP (200× magnifications).
Liu et al. BMC Complementary and Alternative Medicine 2014, 14:303 Page 6 of 6
http://www.biomedcentral.com/1472-6882/14/303to produce any observable changes on AMPK and ACC
phosphorylation.
Unlike γ-T3, PSP has not been shown to regulate either
the cell survival signalling pathways or the metabolic path-
way like AMPK. As expected, treatment of cancer cells
with PSP was unable to induce the phosphorylation of
either AMPK or ACC. It is therefore surprising that in the
presence of PSP, the effect of γ-T3 was drastically en-
hanced. Indeed, at a dose of γ-T3 that failed to induce
AMPK activation, addition of PSP was found to signifi-
cantly upregulate AMPK activation. Since the majority of
the research on PSP were restricted on its immunomodu-
latory effect, it is currently unclear how PSP enhanced the
effect of γ-T3. However, considering the important role of
AMPK activation in inhibiting stem cell self-renewal [16]
and that both γ-T3 and PSP were found to have potent
anti-CSC [2,4], it is tempting to speculate that by combin-
ing PSP and γ-T3, a more potent anti-CSC effect can be
achieved. Indeed, co-treatment of PSP and γ-T3 were
found to achieve a significant tumor suppressive effect
in vivo. Meanwhile, examination of the tumor tissues after
the co-treatment confirmed that AMPK and ACC phos-
phorylation were both upregulated.
Conclusion
In summary, we have demonstrated for the first time that
PSP not only enhance the effect of γ-T3 on AMPK activa-
tion, but also showed that it effectively inhibits tumor
growth in vivo. Our results suggest that combination of
PSP and γ-T3 may be an effective therapeutic strategy for
the treatment of cancers.
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